Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety an... और पढ़ें
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety an... और पढ़ें
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral n... और पढ़ें
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending... और पढ़ें
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozanti... और पढ़ें
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combi... और पढ़ें
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'Complementary Herbal Approach to Rheumatoid Management Study (CHARMS)'. The following are the oth... और पढ़ें
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... और पढ़ें
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... और पढ़ें
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... और पढ़ें